Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04616456 | Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients | EARLY_PHASE1 | COMPLETED | 19 | — | — | Dec 30, 2020 | Jan 30, 2022 | Aug 19, 2022 | 1 | United States |
PET imaging measurement calculated over whole brain within putamen, pons, cerebellum
PET imaging measurement calculated over whole brain within putamen, pons, cerebellum
| Arm | Type | Description |
|---|---|---|
| Multiple System Atrophy (MSA) | EXPERIMENTAL | Twenty to twenty-five subjects with probable MSA diagnosis will be recruited for this study. Each subject will undergo an \[F-18\]PBR06 PET and MRI scan at baseline, and will receive the experimental drug, verdiperstat (BHV-3241) under supervision of clinic staff. A follow-up \[F-18\]PBR06 PET and MRI scan will be performed after 6 months (26 weeks) of taking verdiperstat. |
| Name | Type | Description |
|---|---|---|
| [F-18]PBR06 | DRUG | PET radiopharmaceutical |
| Verdiperstat | DRUG | verdiperstat targets microglial inflammation in the brain |
\*\*Subjects must be located in close proximity to Brigham and Women's Hospital, Boston, MA in order to meet monitoring criteria outlined in study protocol.\*\* Inclusion/Exclusion criteria: Subject Inclusion Criteria: 1\. Probable MSA clinical diagnosis Subject Exclusion Criteria: 1. Individua...